Mazdutide

Name: Mazdutide: A Dual Agonist Weight Loss Treatment
Creator: Wajahet Ali Bhatti
Published: 2026-02-26T12:44:00.000Z

Weight Loss

Written By Wajahet Ali Bhatti - updated 26/02/2026 12:17Reviewed By Sidhi Nathwani - 26/02/2026 12:17

How does Mazdutide work?

Mazdutide is a dual agonist peptide : a glucagon-like peptide-1 (GLP-1) and glucagon receptor (GCGR).This means it works on two hormone pathways in the body, designed to produce a greater weight loss than a GLP-1 alone.

GLP-1: Helps to keep you full, quicker, for longer.

GCGR: Has been shown to reduce body weight and blood glucose levels.

Mazdutide has been trialled in patients with diabetes and has been shown to reduce HbA1c. As well as this, a study observed that 9mg of Mazdutide significantly reduced liver fat content and also a significant reduction in waist circumference.

How effective is Mazdutide?

In early phase trials, doses up to 16mg were administered in adults with overweight or obesity. After 20 weeks, there was a significant amount of weight loss achieved by those in the medication group in comparison to those who administered a placebo.

Cohort	Mean weight loss	Individuals who achieved mean weight loss	Mean change in waist circumference
1 (n=12)	20%	66.7%	12%
2 (n=12)	21%	75%	17%
3 (n=8)	0.1%	-	0.8%

In another trial, consisting of 610 participants, the results demonstrated a clear superior.

Group	Mean change in body weight from baseline \- Week 32	Weight reduction of at least 5%	Mean change in body weight from baseline \- Week 48	Weight reduction of at least 15%
4mg	10.09%	73.9%	11%	35.7%
6mg	12.55%	82%	14.01%	49.5%
Placebo	0.45%	10.5%	0.3%	2.0%

What are the side effects of Mazdutide?

Mazdutide has a similar side effect profile to some of the weight loss medications you may already be familiar with.

Gastrointestinal side effects are the most common. These include:

Nausea
Vomiting
Diarrhoea
Bloating or abdominal discomfort

Upper respiratory tract infections were also reported in some participants. However, this was seen across all participant groups, including the placebo group.

Who would not be suitable for Mazdutide

Mazdutide is currently under development and new information regarding this treatment, including who it will be suitable for, has not yet been confirmed. Based on what we know about GLP-1s, Mazdutide will not be suitable for:

Pregnant or breastfeeding women
Those who have plans to become pregnant in the near future
Individuals who have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2)
A history of pancreatitis
Active gallstones or issues with your gallbladder

Frequently Asked Questions

Everything you need to know

When will Mazdutide be available?

+−

Mazdutide has currently been approved in China and may be approved in the UK in 2026/2027.

What are the side effects of Mazdutide?

+−

Side effects of Mazdutide are similar to those of other GLP-1s. The main side effects are GI related: nausea, vomiting, bloating, diarrhea and constipation.

Is Mazdutide better than other weight loss treatments?

+−

Feature	Mazdutide	Wegovy	Mounjaro	Nevolat
Active ingredient	Mazdutide	Semaglutide	Tirzepatide	Liraglutide
Manufacturer	Eli Lilly, Innovent	Novo Nordisk	Eli Lilly	Zentiva
Doses	2mg, 4mg, 6mg - currently being studied up to 16mg	0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg	2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg	0.6mg, 1.2mg, 1.8mg, 2.4mg, 3.0mg
Hormones targeted	GLP-1 and GCGR	GLP-1	GLP-1 & GIP	GLP-1
Availability	May receive approval in the UK in 2026/2027	Currently available	Currently available	Currently available
Mean weight loss	Up to 21%	Up to 20%	Up to 22.5%	Up to 11%